Skip to main content
VERICI DX PLC logo

VERICI DX PLC — Investor Relations & Filings

Ticker · VRCI ISIN · GB00BM8HZD43 LEI · 213800FI5WE4FVQ3G645 IL Real estate activities
Open in API
Filings indexed 189 across all filing types
Latest filing 2025-11-03 Regulatory Filings
Country GB United Kingdom
Listing IL VRCI

About VERICI DX PLC

https://www.vericidx.com/

Verici Dx is an immuno-diagnostics company developing and commercializing a suite of proprietary tests for the kidney transplant market. The company's platform utilizes artificial intelligence-assisted transcriptomic analysis of RNA signatures to provide data-driven insights to clinicians. These tests are designed to decipher the body's immune response and other biological signals, enabling personalized risk assessment for organ injury, rejection, and graft failure. The goal is to assist clinicians in medical management throughout the transplant process, from pre-transplant to late-stage care, ultimately aiming to improve patient outcomes and long-term graft survival.

Recent filings

Filing Released Lang Actions
Completion of ISO 27001 surveillance audit
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the RNS (Regulatory News Service) announcing the successful completion of an ISO 27001 surveillance audit. It does not contain the audit report itself, but rather announces the achievement of the certification. Since it does not fit into specific categories like financial reports, M&A, or director dealings, and is a general corporate announcement, it is classified as a Regulatory Filing (RNS).
2025-11-03 English
Options revision & Grant of new share options
Remuneration Information Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from Verici Dx plc regarding the repricing of existing share options and the grant of new share options to Directors and PDMRs. While it contains details about director shareholdings, it is primarily an announcement of a corporate action (option grants/repricing) rather than a simple trade notification. It includes the mandatory PDMR notification table required by the Market Abuse Regulation (MAR). Given the focus on management remuneration and option grants, it fits the 'Director's Dealing' (DIRS) category as it details transactions involving company directors and PDMRs.
2025-10-30 English
Board Changes
Board/Management Information Classification · 100% confidence The document is an official announcement from Verici Dx plc regarding changes to its Board of Directors, specifically the appointment of a new Non-executive Director and the resignation of an existing one. It includes biographical details of the new director and required disclosures under AIM Rules. This fits the definition of a Board/Management Information filing.
2025-10-06 English
Update on Tutivia™ test adoption
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from Verici Dx plc regarding operational updates (Tutivia test adoption) and an upcoming investor presentation. It does not contain full financial statements, nor is it a report publication announcement for a specific document; it is a general corporate update regarding business progress and investor relations. As it does not fit into specific categories like 10-K, ER, or IP (it is an announcement *about* an upcoming presentation, not the presentation itself), it falls under the RNS fallback category.
2025-10-06 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by Verici Dx PLC. It details the acquisition or disposal of voting rights by Harwood Capital LLP, crossing specific regulatory thresholds. This is a standard regulatory disclosure for major shareholding notifications, which corresponds to the 'Major Shareholding Notification' category.
2025-10-01 English
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half-year report' for Verici Dx plc for the period ended 30 June 2025. It contains detailed financial highlights (revenue, EBITDA, cash balance), operational highlights, and a comprehensive 'Chief Executive Officer's Report' discussing business strategy, product performance, and financial outlook. As it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2025
2025-09-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.